Novartis pharma sales down in 4Q, but Alcon and Sandoz units see profits
This article was originally published in Scrip
Executive Summary
Novartis's pharmaceutical sales struggled in the fourth quarter of 2014 because of increased generic competition, but its own generics division Sandoz and ophthalmology unit Alcon both saw increases in the quarter.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.